Prestige Consumer Healthcare Q2 revenue beats on acquisition boost

What happened

Prestige Consumer Healthcare said Q2 revenue rose 22.7%, beating analyst expectations, while adjusted diluted earnings per share increased to $1.13 from $1.07 a year earlier. The company lowered its fiscal 2027 revenue and earnings outlook, citing Clear Eyes supply constraints expected to weigh on second-half revenue.

Confirmed

Global impact / market context

The acquisition contributions that lifted revenue did not prevent the company from cutting its outlook: Clear Eyes supply problems are expected to weigh on second-half sales. If constraints persist, fewer products available to sell could limit revenue and weaken the benefit from acquired brands.

Analyst inference

The article presents a mixed operating picture: Q2 revenue beat analysts’ estimate and adjusted earnings per share increased, but organic revenue fell because of lower Clear Eyes sales and order timing. The lowered forecast may shift investor attention from reported growth to supply recovery and underlying sales.

Analyst inference

What to watch

1. Watch whether Clear Eyes supply constraints ease, since the company expects them to weigh on second-half revenue and has lowered its fiscal 2027 outlook. Analyst inference
2. Track sales from Breathe Right and LaCorium, whose acquisitions contributed to revenue growth in both North American and International segments. Confirmed
3. Compare future results with the company’s lowered fiscal 2027 revenue and adjusted diluted earnings per share outlook, assessing whether supply issues and sales trends remain consistent. Confirmed

Evidence

• Original source link unavailable